Cargando…

Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study

BACKGROUND: Myeloproliferative neoplasms (MPNs) are a group of myeloid malignancies associated with significant symptom burden. Despite pharmacological advances in therapies, inadequate management of MPN symptoms results in reduced quality of life. OBJECTIVE: This study aims to determine the feasibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Win, Hninyee, Russell, Samantha, Wertheim, Betsy C, Maizes, Victoria, Crocker, Robert, Brooks, Audrey J, Mesa, Ruben, Huberty, Jennifer, Geyer, Holly, Eckert, Ryan, Larsen, Ashley, Gowin, Krisstina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015738/
https://www.ncbi.nlm.nih.gov/pubmed/35357315
http://dx.doi.org/10.2196/33581
_version_ 1784688373728804864
author Win, Hninyee
Russell, Samantha
Wertheim, Betsy C
Maizes, Victoria
Crocker, Robert
Brooks, Audrey J
Mesa, Ruben
Huberty, Jennifer
Geyer, Holly
Eckert, Ryan
Larsen, Ashley
Gowin, Krisstina
author_facet Win, Hninyee
Russell, Samantha
Wertheim, Betsy C
Maizes, Victoria
Crocker, Robert
Brooks, Audrey J
Mesa, Ruben
Huberty, Jennifer
Geyer, Holly
Eckert, Ryan
Larsen, Ashley
Gowin, Krisstina
author_sort Win, Hninyee
collection PubMed
description BACKGROUND: Myeloproliferative neoplasms (MPNs) are a group of myeloid malignancies associated with significant symptom burden. Despite pharmacological advances in therapies, inadequate management of MPN symptoms results in reduced quality of life. OBJECTIVE: This study aims to determine the feasibility of a 12-week global wellness mobile app intervention in decreasing MPN symptom burden. The University of Arizona Andrew Weil Center for Integrative Medicine’s global wellness mobile app, My Wellness Coach (MWC), guides patients to improve their health and well-being through facilitating behavior changes. METHODS: Of the 30 patients enrolled in a 12-week intervention, 16 (53%) were retained through the final assessment. Feasibility was assessed by the ease of recruitment, participant adherence, and mobile app acceptability. App acceptability was measured using the user version of the Mobile Application Rating Scale. MPN symptom burden was measured at baseline and 12 weeks after the intervention. RESULTS: Recruitment was efficient, with the participant goal reached within a 60-day period, suggestive of a demand for such an intervention. Adherence was less than the target within study design (75%), although similar to mobile device app use in other studies (53%). The app was deemed acceptable based on the mean user version of the Mobile Application Rating Scale 3-star rating by participants. Finally, there were statistically significant improvements in several MPN symptoms, quality of life, and total score on the Myeloproliferative Neoplasm Symptom Assessment Form surveys. CONCLUSIONS: Our 12-week intervention with the MWC app was feasible and was associated with a decrease in MPN symptom burden. Further investigation of the MWC app for use as a self-management strategy to reduce the symptom burden in patients with MPN is warranted.
format Online
Article
Text
id pubmed-9015738
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher JMIR Publications
record_format MEDLINE/PubMed
spelling pubmed-90157382022-04-19 Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study Win, Hninyee Russell, Samantha Wertheim, Betsy C Maizes, Victoria Crocker, Robert Brooks, Audrey J Mesa, Ruben Huberty, Jennifer Geyer, Holly Eckert, Ryan Larsen, Ashley Gowin, Krisstina JMIR Form Res Original Paper BACKGROUND: Myeloproliferative neoplasms (MPNs) are a group of myeloid malignancies associated with significant symptom burden. Despite pharmacological advances in therapies, inadequate management of MPN symptoms results in reduced quality of life. OBJECTIVE: This study aims to determine the feasibility of a 12-week global wellness mobile app intervention in decreasing MPN symptom burden. The University of Arizona Andrew Weil Center for Integrative Medicine’s global wellness mobile app, My Wellness Coach (MWC), guides patients to improve their health and well-being through facilitating behavior changes. METHODS: Of the 30 patients enrolled in a 12-week intervention, 16 (53%) were retained through the final assessment. Feasibility was assessed by the ease of recruitment, participant adherence, and mobile app acceptability. App acceptability was measured using the user version of the Mobile Application Rating Scale. MPN symptom burden was measured at baseline and 12 weeks after the intervention. RESULTS: Recruitment was efficient, with the participant goal reached within a 60-day period, suggestive of a demand for such an intervention. Adherence was less than the target within study design (75%), although similar to mobile device app use in other studies (53%). The app was deemed acceptable based on the mean user version of the Mobile Application Rating Scale 3-star rating by participants. Finally, there were statistically significant improvements in several MPN symptoms, quality of life, and total score on the Myeloproliferative Neoplasm Symptom Assessment Form surveys. CONCLUSIONS: Our 12-week intervention with the MWC app was feasible and was associated with a decrease in MPN symptom burden. Further investigation of the MWC app for use as a self-management strategy to reduce the symptom burden in patients with MPN is warranted. JMIR Publications 2022-03-31 /pmc/articles/PMC9015738/ /pubmed/35357315 http://dx.doi.org/10.2196/33581 Text en ©Hninyee Win, Samantha Russell, Betsy C Wertheim, Victoria Maizes, Robert Crocker, Audrey J Brooks, Ruben Mesa, Jennifer Huberty, Holly Geyer, Ryan Eckert, Ashley Larsen, Krisstina Gowin. Originally published in JMIR Formative Research (https://formative.jmir.org), 31.03.2022. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Formative Research, is properly cited. The complete bibliographic information, a link to the original publication on https://formative.jmir.org, as well as this copyright and license information must be included.
spellingShingle Original Paper
Win, Hninyee
Russell, Samantha
Wertheim, Betsy C
Maizes, Victoria
Crocker, Robert
Brooks, Audrey J
Mesa, Ruben
Huberty, Jennifer
Geyer, Holly
Eckert, Ryan
Larsen, Ashley
Gowin, Krisstina
Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study
title Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study
title_full Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study
title_fullStr Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study
title_full_unstemmed Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study
title_short Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study
title_sort mobile app intervention on reducing the myeloproliferative neoplasm symptom burden: pilot feasibility and acceptability study
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015738/
https://www.ncbi.nlm.nih.gov/pubmed/35357315
http://dx.doi.org/10.2196/33581
work_keys_str_mv AT winhninyee mobileappinterventiononreducingthemyeloproliferativeneoplasmsymptomburdenpilotfeasibilityandacceptabilitystudy
AT russellsamantha mobileappinterventiononreducingthemyeloproliferativeneoplasmsymptomburdenpilotfeasibilityandacceptabilitystudy
AT wertheimbetsyc mobileappinterventiononreducingthemyeloproliferativeneoplasmsymptomburdenpilotfeasibilityandacceptabilitystudy
AT maizesvictoria mobileappinterventiononreducingthemyeloproliferativeneoplasmsymptomburdenpilotfeasibilityandacceptabilitystudy
AT crockerrobert mobileappinterventiononreducingthemyeloproliferativeneoplasmsymptomburdenpilotfeasibilityandacceptabilitystudy
AT brooksaudreyj mobileappinterventiononreducingthemyeloproliferativeneoplasmsymptomburdenpilotfeasibilityandacceptabilitystudy
AT mesaruben mobileappinterventiononreducingthemyeloproliferativeneoplasmsymptomburdenpilotfeasibilityandacceptabilitystudy
AT hubertyjennifer mobileappinterventiononreducingthemyeloproliferativeneoplasmsymptomburdenpilotfeasibilityandacceptabilitystudy
AT geyerholly mobileappinterventiononreducingthemyeloproliferativeneoplasmsymptomburdenpilotfeasibilityandacceptabilitystudy
AT eckertryan mobileappinterventiononreducingthemyeloproliferativeneoplasmsymptomburdenpilotfeasibilityandacceptabilitystudy
AT larsenashley mobileappinterventiononreducingthemyeloproliferativeneoplasmsymptomburdenpilotfeasibilityandacceptabilitystudy
AT gowinkrisstina mobileappinterventiononreducingthemyeloproliferativeneoplasmsymptomburdenpilotfeasibilityandacceptabilitystudy